?R35 Abstract *REVISED* Tannishtha Reya, Ph.D Grant # 1R35CA197699-01 Over the last few decades our remarkable understanding of the molecular basis of oncogenesis has begun to influence cancer therapy at many levels. In the recent past this has led us away from simply relying on blunt tools like chemotherapy and radiation and towards including and designing more molecularly-targeted therapies. Despite these advances, cancer continues to claim millions of lives worldwide. In some very significant part this extraordinary toll is due to our inability to detect the disease early. Early detection of cancer vastly increases the likelihood of effective and durable responses to therapy, and can make the difference between life and death. Considering the potential impact of effective early detection, research in this area lags markedly behind the development of therapeutics. While the field of cancer research has largely focused on developing new therapeutics, there is a critical need to combine this effort with designing new and sensitive strategies that will allow effective early detection. The work we describe here focuses on bridging this gap and providing a more balanced approach to controlling cancer, by combining molecular strategies for design and development of early detection tools coupled with understanding of control points of the transition from benign hyperproliferative phase to a more malignant phase, allowing development of new therapies that can be used for more effective interventions.

Public Health Relevance

The primary focus of my work has been to understand the mechanisms by which cancers subvert normal developmental and stem cell signals to grow, spread and evade therapy. Over the last decade our work has ranged from discovery of new signals involved in cancer growth and progression to preclinical work that has formed the basis of clinical trials testing new agents for drug-resistant leukemias. In the coming years, we will continue to strive to make important contributions that will have a meaningful impact on the many lives that deeply depend on the discoveries we make as a community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
1R35CA197699-01
Application #
8956344
Study Section
Special Emphasis Panel (ZCA1-GRB-P (M1))
Program Officer
Mohla, Suresh
Project Start
2015-08-12
Project End
2022-07-31
Budget Start
2015-08-12
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$913,500
Indirect Cost
$313,500
Name
University of California San Diego
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Dravis, Christopher; Chung, Chi-Yeh; Lytle, Nikki K et al. (2018) Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. Cancer Cell 34:466-482.e6
Todoric, Jelena; Antonucci, Laura; Di Caro, Giuseppe et al. (2017) Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell 32:824-839.e8
Hui, Sheng; Ghergurovich, Jonathan M; Morscher, Raphael J et al. (2017) Glucose feeds the TCA cycle via circulating lactate. Nature 551:115-118
Bajaj, Jeevisha; Konuma, Takaaki; Lytle, Nikki K et al. (2016) CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. Cancer Cell 30:792-805
Fox, Raymond G; Lytle, Nikki K; Jaquish, Dawn V et al. (2016) Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534:407-411
Koechlein, Claire S; Harris, Jeffrey R; Lee, Timothy K et al. (2016) High-resolution imaging and computational analysis of haematopoietic cell dynamics in vivo. Nat Commun 7:12169